Moreover, this established S1R agonist appeared to be ideal as a “model drug” for us to validate our experimental setting of retinal illumination in Abca4−/−Rdh8−/− mice related to AMD pathology. The gene discussed is TMBIM4; the disease is age-related macular degeneration.